Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.
2.

Dopamine D1 receptor subtype mediates acute stress-induced dendritic growth in excitatory neurons of the medial prefrontal cortex and contributes to suppression of stress susceptibility in mice.

Shinohara R, Taniguchi M, Ehrlich AT, Yokogawa K, Deguchi Y, Cherasse Y, Lazarus M, Urade Y, Ogawa A, Kitaoka S, Sawa A, Narumiya S, Furuyashiki T.

Mol Psychiatry. 2018 Aug;23(8):1717-1730. doi: 10.1038/mp.2017.177. Epub 2017 Sep 19.

PMID:
28924188
3.

Redescriptions of two closely related East Asian flatfish species of the genus <i>Pleuronichthys</i>.

Yokogawa K, Watanabe KI, Ogihara G.

Zootaxa. 2016 Dec 4;4205(1):zootaxa.4205.1.1. doi: 10.11646/zootaxa.4205.1.1.

PMID:
27988592
4.

Inhibitory effects of Ecklonia cava extract on high glucose-induced hepatic stellate cell activation.

Yokogawa K, Matsui-Yuasa I, Tamura A, Terada M, Kojima-Yuasa A.

Mar Drugs. 2011 Dec;9(12):2793-808. doi: 10.3390/md9122793. Epub 2011 Dec 20.

5.

Uniaxial strain orientation dependence of superconducting transition temperature (Tc) and critical superconducting pressure (Pc) in β-(BDA-TTP)2I3.

Kikuchi K, Isono T, Kojima M, Yoshimoto H, Kodama T, Fujita W, Yokogawa K, Yoshino H, Murata K, Kaihatsu T, Akutsu H, Yamada J.

J Am Chem Soc. 2011 Dec 14;133(49):19590-3. doi: 10.1021/ja207353x. Epub 2011 Nov 16.

PMID:
22074598
6.

Structural units and their periodicity in carbon nanotubes.

Long D, An B, Yokogawa K, Ling L, Miyawaki J, Mochida I, Yoon SH.

Small. 2010 Nov 22;6(22):2526-9. doi: 10.1002/smll.201001263. No abstract available.

PMID:
20941776
7.

[A comparative study of concurrent chemoradiotherapy with S-1 or CDDP for pharyngeal or laryngeal cancer].

Kuratomi Y, Satoh S, Monji M, Yokogawa K, Suzuki K, Shimazu R, Tokumaru S, Inokuchi A.

Gan To Kagaku Ryoho. 2010 Aug;37(8):1471-6. Japanese.

PMID:
20716870
8.

Evaluation of selective competitive binding of basic drugs to alpha1-acid glycoprotein variants.

Ishizaki J, Fukaishi A, Fukuwa C, Yamazaki S, Tabata M, Ishida T, Suga Y, Arai K, Yokogawa K, Miyamoto K.

Biol Pharm Bull. 2010;33(1):95-9.

9.

Pore structure analysis of activated carbon fiber by microdomain-based model.

Shiratori N, Lee KJ, Miyawaki J, Hong SH, Mochida I, An B, Yokogawa K, Jang J, Yoon SH.

Langmuir. 2009 Jul 7;25(13):7631-7. doi: 10.1021/la9000347.

PMID:
19344158
10.

Pressure transmitting medium Daphne 7474 solidifying at 3.7 GPa at room temperature.

Murata K, Yokogawa K, Yoshino H, Klotz S, Munsch P, Irizawa A, Nishiyama M, Iizuka K, Nanba T, Okada T, Shiraga Y, Aoyama S.

Rev Sci Instrum. 2008 Aug;79(8):085101. doi: 10.1063/1.2964117.

PMID:
19044374
11.

Selective drug delivery to bone using acidic oligopeptides.

Ishizaki J, Waki Y, Takahashi-Nishioka T, Yokogawa K, Miyamoto K.

J Bone Miner Metab. 2009;27(1):1-8. doi: 10.1007/s00774-008-0004-z. Epub 2008 Nov 19. Review. No abstract available.

PMID:
19018455
12.

Apparatus for material tests using an internal loading system in high-pressure gas at room temperature.

Imade M, Fukuyama S, Yokogawa K.

Rev Sci Instrum. 2008 Jul;79(7):073903. doi: 10.1063/1.2953091.

PMID:
18681712
13.

Bone-targeting of quinolones conjugated with an acidic oligopeptide.

Takahashi T, Yokogawa K, Sakura N, Nomura M, Kobayashi S, Miyamoto K.

Pharm Res. 2008 Dec;25(12):2881-8. doi: 10.1007/s11095-008-9605-4. Epub 2008 Jul 29.

PMID:
18663412
14.

Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas.

Kawahara M, Takahashi Y, Takazawa K, Tsuchiya H, Tomita K, Yokogawa K, Miyamoto K.

Anticancer Res. 2008 May-Jun;28(3A):1681-5.

15.

Inhibitory mechanisms of flavonoids on insulin-stimulated glucose uptake in MC3T3-G2/PA6 adipose cells.

Nomura M, Takahashi T, Nagata N, Tsutsumi K, Kobayashi S, Akiba T, Yokogawa K, Moritani S, Miyamoto K.

Biol Pharm Bull. 2008 Jul;31(7):1403-9.

16.

Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs.

Takahashi-Nishioka T, Yokogawa K, Tomatsu S, Nomura M, Kobayashi S, Miyamoto K.

Curr Drug Discov Technol. 2008 Mar;5(1):39-48. Review.

PMID:
18537566
17.

Serum concentrations of laminin gamma2 fragments in patients with head and neck squamous cell carcinoma.

Kuratomi Y, Sato S, Monji M, Shimazu R, Tanaka G, Yokogawa K, Inoue A, Inokuchi A, Katayama M.

Head Neck. 2008 Aug;30(8):1058-63. doi: 10.1002/hed.20838.

PMID:
18446818
18.

Soybean fat supplementation controls insulin resistance caused by fat-free total parenteral nutrition.

Ohkawa H, Fukuwa C, Matsuzawa-Nagata N, Yokogawa K, Omura K, Miyamoto K.

J Pharm Pharmacol. 2008 Apr;60(4):461-5. doi: 10.1211/jpp.60.4.0008.

PMID:
18380918
19.

Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B.

Ishizaki J, Ito S, Jin M, Shimada T, Ishigaki T, Harasawa Y, Yokogawa K, Takami A, Nakao S, Miyamoto K.

Biopharm Drug Dispos. 2008 May;29(4):195-203. doi: 10.1002/bdd.604.

PMID:
18240156
20.

Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.

Khemawoot P, Nishino K, Ishizaki J, Yokogawa K, Miyamoto K.

Eur J Pharmacol. 2007 Nov 21;574(1):71-6. Epub 2007 Jun 29.

PMID:
17651723
21.

Influence of chronic hepatic failure on disposition kinetics of valproate excretion through a phase II reaction in rats treated with carbon tetrachloride.

Khemawoot P, Maruyama C, Tsukada H, Noda H, Ishizaki J, Yokogawa K, Miyamoto K.

Biopharm Drug Dispos. 2007 Sep;28(6):331-8.

PMID:
17617793
22.

Involvement of alpha1-acid glycoprotein in inter-individual variation of disposition kinetics of ropivacaine following epidural infusion in off-pump coronary artery bypass grafting.

Yokogawa K, Shimomura S, Ishizaki J, Shimada T, Fukuwa C, Kawada M, Tsubokawa T, Yamamoto K, Miyamoto K.

J Pharm Pharmacol. 2007 Jan;59(1):67-73.

PMID:
17227622
23.

Structure-activity relationship of flavonoids for inhibition of epidermal growth factor-induced transformation of JB6 Cl 41 cells.

Ichimatsu D, Nomura M, Nakamura S, Moritani S, Yokogawa K, Kobayashi S, Nishioka T, Miyamoto K.

Mol Carcinog. 2007 Jun;46(6):436-45.

PMID:
17219438
24.

Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.

Khemawoot P, Yokogawa K, Shimada T, Miyamoto K.

Biochem Pharmacol. 2007 Jan 1;73(1):155-62. Epub 2006 Sep 14.

PMID:
17049493
25.

Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice.

Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K.

Biochem Pharmacol. 2006 Oct 16;72(8):1042-50. Epub 2006 Aug 30.

PMID:
16939683
26.

Development of dosage design of hepatic metabolizing drugs using serum albumin level in chronic hepatic failure.

Mano Y, Tsukada H, Kurihara T, Nomura M, Yokogawa K, Miyamoto K.

Biol Pharm Bull. 2006 Aug;29(8):1692-9.

27.

Magnetoresistance effects evidencing the pi-d interaction in metallic organic conductors, (EDT-DSDTFVO)2*MX4 (M = Fe, Ga; X = Cl, Br).

Fujiwara H, Hayashi T, Sugimoto T, Nakazumi H, Noguchi S, Li L, Yokogawa K, Yasuzuka S, Murata K, Mori T.

Inorg Chem. 2006 Jul 24;45(15):5712-4.

PMID:
16841967
28.

Phosphodiesterase 4 inhibitor rolipram potentiates the inhibitory effect of calcitonin on osteoclastogenesis.

Miyamoto K, Nishioka T, Waki Y, Nomura M, Katsuta H, Yokogawa K, Amano H.

J Bone Miner Metab. 2006;24(4):260-5.

PMID:
16816919
29.
30.

Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol.

Yokogawa K, Toshima K, Yamoto K, Nishioka T, Sakura N, Miyamoto K.

Biol Pharm Bull. 2006 Jun;29(6):1229-33.

32.

Serum aminotransferase activity as a predictor for estimation of total clearance of hepatically metabolized drugs in rats with acute hepatic failure.

Yokogawa K, Ido A, Kurihara T, Mano Y, Nomura M, Ishizaki J, Miyamoto K.

Biol Pharm Bull. 2006 Jan;29(1):141-5.

33.

Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone.

Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, Miyamoto K.

Int J Pharm. 2006 Feb 17;309(1-2):81-6. Epub 2005 Dec 27.

PMID:
16384676
34.

Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine.

Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K.

Drug Metab Pharmacokinet. 2005 Oct;20(5):324-30.

35.

Insulin signaling in adipocytes differentiated from mouse stromal MC3T3-G2/PA6 cells.

Morito S, Yaguchi K, Imada M, Tachikawa C, Nomura M, Moritani S, Igarashi M, Yokogawa K, Miyamoto K.

Biol Pharm Bull. 2005 Nov;28(11):2040-5.

36.

Stable metallic behavior and antiferromagnetic ordering of Fe(III) d spins in (EDO-TTFVO)2.FeCl4.

Fujiwara H, Wada K, Hiraoka T, Hayashi T, Sugimoto T, Nakazumi H, Yokogawa K, Teramura M, Yasuzuka S, Murata K, Mori T.

J Am Chem Soc. 2005 Oct 19;127(41):14166-7.

PMID:
16218594
37.

The influence of the sennosides on absorption of glycyrrhetic acid in rats.

Mizuhara Y, Takizawa Y, Ishihara K, Asano T, Kushida H, Morota T, Kase Y, Takeda S, Aburada M, Nomura M, Yokogawa K.

Biol Pharm Bull. 2005 Oct;28(10):1897-902.

38.

Involvement of ABC transporters in chemosensitivity of human renal cell carcinoma, and regulation of MRP2 expression by conjugated bilirubin.

Nomura M, Matsunami T, Kobayashi K, Uchibayashi T, Koshida K, Tanaka M, Namiki M, Mizuhara Y, Akiba T, Yokogawa K, Moritani S, Miyamoto K.

Anticancer Res. 2005 Jul-Aug;25(4):2729-35.

39.

Inhibition of epidermal growth factor-induced cell transformation and Akt activation by caffeine.

Nomura M, Ichimatsu D, Moritani S, Koyama I, Dong Z, Yokogawa K, Miyamoto K.

Mol Carcinog. 2005 Sep;44(1):67-76.

PMID:
16044420
40.

Antitumor effect of geranylamine derivatives on human hepatoma.

Akiyama K, Kumamoto T, Wada S, Miura H, Nomura M, Yokogawa K, Miyamoto K.

In Vivo. 2005 Jan-Feb;19(1):173-8.

41.

Cremophor EL releases cyclosporin A adsorbed on blood cells and blood vessels, and increases apparent plasma concentration of cyclosporin A.

Jin M, Shimada T, Yokogawa K, Nomura M, Mizuhara Y, Furukawa H, Ishizaki J, Miyamoto K.

Int J Pharm. 2005 Apr 11;293(1-2):137-44.

PMID:
15778051
42.

Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.

Shimada T, Nomura M, Yokogawa K, Endo Y, Sasaki T, Miyamoto K, Yonemura Y.

J Pharm Pharmacol. 2005 Feb;57(2):177-81.

PMID:
15720780
43.

Inhibitory mechanism of caffeine on insulin-stimulated glucose uptake in adipose cells.

Akiba T, Yaguchi K, Tsutsumi K, Nishioka T, Koyama I, Nomura M, Yokogawa K, Moritani S, Miyamoto K.

Biochem Pharmacol. 2004 Nov 15;68(10):1929-37.

PMID:
15476664
44.

Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.

Yokogawa K, Jin M, Furui N, Yamazaki M, Yoshihara H, Nomura M, Furukawa H, Ishizaki J, Fushida S, Miwa K, Miyamoto K.

J Pharm Pharmacol. 2004 May;56(5):629-34.

PMID:
15142340
45.

Conjugated bilirubin induces multidrug resistance-associated protein 2 mRNA expression and in vivo cisplatin resistance in rat hepatoma AH66 cells.

Tamai M, Ito Y, Mirura H, Tsukada H, Yokogawa K, Nomura M, Moritani S, Miyamoto K.

Anticancer Res. 2003 Nov-Dec;23(6C):4781-7.

PMID:
14981926
46.

Rapid determination method of caffeine and application to monitoring of caffeine-assisted chemotherapy.

Kawahara M, Kagiyama H, Kanazawa Y, Tsuchiya H, Tomita K, Yokogawa K, Miyamoto K.

Biopharm Drug Dispos. 2004 Mar;25(2):61-7.

PMID:
14872553
47.

Serum aminotransferase activity as a predictor of clearance of drugs metabolized by CYP isoforms in rats with acute hepatic failure induced by carbon tetrachloride.

Yokogawa K, Watanabe M, Takeshita H, Nomura M, Mano Y, Miyamoto K.

Int J Pharm. 2004 Jan 28;269(2):479-89.

PMID:
14706259
48.

High bioavailabilty of alpha-tocopherol loaded into poly (DL-lactic-co-glycolic acid) microspheres in apolipoprotein B knockout mice.

Yokogawa K, Shima Y, Hashimoto T, Hiyajyo M, Kadoyama K, Ishizaki J, Nomura M, Miyamoto K.

Pharm Res. 2003 Nov;20(11):1846-50.

PMID:
14661931
49.

[Objective evaluation of clinical pharmacy lectures and experience in a master program using visual analog scale method].

Naruhashi K, Nomura M, Kamei H, Ono S, Matsushita R, Shimizu S, Yokogawa K, Yamada K, Suzuki N, Miyamoto K, Kimura K.

Yakugaku Zasshi. 2003 Nov;123(11):973-80. Japanese.

50.

Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2.

Yamagami H, Nishioka T, Ochiai E, Fukushima K, Nomura M, Kasugai S, Moritani S, Yokogawa K, Miyamoto K.

Biochem Pharmacol. 2003 Sep 1;66(5):801-7.

PMID:
12948861

Supplemental Content

Loading ...
Support Center